4.6 Article

Clinical and Microbiological Features of HIV-Associated Tuberculous Meningitis in Vietnamese Adults

期刊

PLOS ONE
卷 3, 期 3, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0001772

关键词

-

资金

  1. Wellcome Trust, UK

向作者/读者索取更多资源

Methods: The aim of this prospective, observational cohort study was to determine the clinical and microbiological features, outcome, and baseline variables predictive of death, in Vietnamese adults with HIV-associated tuberculous meningitis (TBM). 58 patients were admitted to the Hospital for Tropical Diseases in Ho Chi Minh City and underwent routine clinical and laboratory assessments. Treatment was with standard antituberculous therapy and adjunctive dexamethasone; antiretroviral therapy was not routinely available. Patients were followed up until the end of TB treatment or death. Results: The median symptom duration was 11 days (range 2-90 days), 21.8% had a past history of TB, and 41.4% had severe (grade 3) TBM. The median CD4 count was 32 cells/mm(3). CSF findings were as follows: median leucocyte count 438610 9 cells/l (63% neutrophils), 69% smear positive and 87.9% culture positive. TB drug resistance rates were high (13% mono-resistance 32.6% poly-resistance 8.7% multidrug resistance). 17% patients developed further AIDS-defining illnesses. 67.2% died (median time to death 20 days). Three baseline variables were predictive of death by multivariate analysis: increased TBM grade [adjusted hazard ratio (AHR) 1.73, 95% CI 1.08-2.76, p = 0.02], lower serum sodium (AHR 0.93, 95% CI 0.89 to 0.98, p = 0.002) and decreased CSF lymphocyte percentage (AHR 0.98, 95% CI 0.97 to 0.99, p = 0.003). Conclusions: HIV-associated TBM is devastating disease with a dismal prognosis. CSF findings included CSF neutrophil predominance, high rates of smear and culture positivity, and high rates of antituberculous drug resistance. Three baseline variables were independently associated with death: increased TBM grade; low serum sodium and decreased CSF lymphocyte percentage.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Medicine, General & Internal

Dexamethasone in Hospitalized Patients with Covid-19

Peter Horby, Wei Shen Lim, Jonathan R. Emberson, Marion Mafham, Jennifer L. Bell, Louise Linsell, Natalie Staplin, Christopher Brightling, Andrew Ustianowski, Einas Elmahi, Benjamin Prudon, Christopher Green, Timothy Felton, David Chadwick, Kanchan Rege, Christopher Fegan, Lucy C. Chappell, Saul N. Faust, Thomas Jaki, Katie Jeffery, Alan Montgomery, Kathryn Rowan, Edmund Juszczak, J. Kenneth Baillie, Richard Haynes, Martin J. Landray

Summary: In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Multidisciplinary Sciences

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Dami A. Collier, Anna De Marco, Isabella A. T. M. Ferreira, Bo Meng, Rawlings P. Datir, Alexandra C. Walls, Steven A. Kemp, Jessica Bassi, Dora Pinto, Chiara Silacci-Fregni, Siro Bianchi, M. Alejandra Tortorici, John Bowen, Katja Culap, Stefano Jaconi, Elisabetta Cameroni, Gyorgy Snell, Matteo S. Pizzuto, Alessandra Franzetti Pellanda, Christian Garzoni, Agostino Riva, Anne Elmer, Nathalie Kingston, Barbara Graves, Laura E. Mccoy, Kenneth G. C. Smith, John R. Bradley, Nigel Temperton, Lourdes Ceron-Gutierrez, Gabriela Barcenas-Morales, William Harvey, Herbert W. Virgin, Antonio Lanzavecchia, Luca Piccoli, Rainer Doffinger, Mark Wills, David Veesler, Davide Corti, Ravindra K. Gupta

Summary: The B.1.1.7 variant of SARS-CoV-2 exhibited reduced neutralization by vaccines and antibodies from recovered COVID-19 patients, with a more substantial loss seen when introducing the E484K mutation. This mutation poses a threat to the efficacy of the BNT162b2 vaccine.

NATURE (2021)

Article Multidisciplinary Sciences

SARS-CoV-2 evolution during treatment of chronic infection

Steven A. Kemp, Dami A. Collier, Rawlings P. Datir, Isabella A. T. M. Ferreira, Salma Gayed, Aminu Jahun, Myra Hosmillo, Chloe Rees-Spear, Petra Mlcochova, Ines Ushiro Lumb, David J. Roberts, Anita Chandra, Nigel Temperton, Katherine Sharrocks, Elizabeth Blane, Yorgo Modis, Kendra E. Leigh, John A. G. Briggs, Marit J. van Gils, Kenneth G. C. Smith, John R. Bradley, Chris Smith, Rainer Doffinger, Lourdes Ceron-Gutierrez, Gabriela Barcenas-Morales, David D. Pollock, Richard A. Goldstein, Anna Smielewska, Jordan P. Skittrall, Theodore Gouliouris, Ian G. Goodfellow, Effrossyni Gkrania-Klotsas, Christopher J. R. Illingworth, Laura E. McCoy, Ravindra K. Gupta

Summary: Chronic infection with SARS-CoV-2 can lead to viral evolution and increased resistance to neutralizing antibodies in immunosuppressed individuals treated with convalescent plasma. During convalescent plasma therapy, there were significant shifts in the viral population structure and sensitivity, suggesting strong selection pressure on the virus during treatment.

NATURE (2021)

Article Biology

Genomic epidemiology of COVID-19 in care homes in the east of England

William L. Hamilton, Gerry Tonkin-Hill, Emily R. Smith, Dinesh Aggarwal, Charlotte J. Houldcroft, Ben Warne, Luke W. Meredith, Myra Hosmillo, Aminu S. Jahun, Martin D. Curran, Surendra Parmar, Laura G. Caller, Sarah L. Caddy, Fahad A. Khokhar, Anna Yakovleva, Grant Hall, Theresa Feltwell, Malte L. Pinckert, Iliana Georgana, Yasmin Chaudhry, Colin S. Brown, Sonia Goncalves, Roberto Amato, Ewan M. Harrison, Nicholas M. Brown, Mathew A. Beale, Michael Spencer Chapman, David K. Jackson, Ian Johnston, Alex Alderton, John Sillitoe, Cordelia Langford, Gordon Dougan, Sharon J. Peacock, Dominic P. Kwiatowski, Ian G. Goodfellow, M. Estee Torok

Summary: COVID-19 poses significant challenges in care homes due to high mortality rates and varied patterns of viral transmission. Limiting viral spread within care homes is crucial to reducing COVID-19 mortality in this population.
Letter Infectious Diseases

Applying prospective genomic surveillance to support investigation of hospital-onset COVID-19

William L. Hamilton, Tom Fieldman, Aminu Jahun, Ben Warne, Christopher J. R. Illingworth, Chris Jackson, Beth Blane, Elinor Moore, Michael P. Weekes, Sharon J. Peacock, Daniela De Angelis, Ian Goodfellow, Theodore Gouliouris, M. Estee Torok

LANCET INFECTIOUS DISEASES (2021)

Article Multidisciplinary Sciences

Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England

Erik Volz, Swapnil Mishra, Meera Chand, Jeffrey C. Barrett, Robert Johnson, Lily Geidelberg, Wes R. Hinsley, Daniel J. Laydon, Gavin Dabrera, Aine O. Toole, Robert Amato, Manon Ragonnet-Cronin, Ian Harrison, Ben Jackson, Cristina Ariani, Olivia Boyd, Nicholas J. Loman, John T. McCrone, Sonia Goncalves, David Jorgensen, Richard Myers, Verity Hill, David K. Jackson, Katy Gaythorpe, Natalie Groves, John Sillitoe, Dominic P. Kwiatkowski, Seth Flaxman, Oliver Ratmann, Samir Bhatt, Susan Hopkins, Axel Gandy, Andrew Rambaut, Neil M. Ferguson

Summary: Genetic and testing data from England indicate that the SARS-CoV-2 variant B.1.1.7 has a transmission advantage over other lineages, showing a rapid expansion during autumn 2020. Analysis of S gene target failures (SGTF) in community-based diagnostic PCR testing suggests that B.1.1.7 is more transmissible than non-variant of concern lineages and has a significant transmission advantage, with a reproduction number 50% to 100% higher. Additionally, cases of B.1.1.7 appear to include a larger share of under 20-year-olds compared to non-variant cases.

NATURE (2021)

Article Biology

Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection

Nick K. Jones, Lucy Rivett, Shaun Seaman, Richard J. Samworth, Ben Warne, Chris Workman, Mark Ferris, Jo Wright, Natalie Quinnell, Ashley Shaw, Ian G. Goodfellow, Paul J. Lehner, Rob Howes, Giles Wright, Nicholas J. Matheson, Michael P. Weekes

Summary: Research shows that there is a fourfold reduction in asymptomatic infection among healthcare workers post-vaccination with the first dose of the BNT162b2 vaccine. This indicates that a single dose of the vaccine can provide short-term protection against asymptomatic SARS-CoV-2 infection, reducing virus transmission and the burden of COVID-19 disease.
Article Public, Environmental & Occupational Health

Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study

Mark S. Graham, Carole H. Sudre, Anna May, Michela Antonelli, Benjamin Murray, Thomas Varsaysky, Kerstin Klaser, Liane S. Canas, Erika Molteni, Marc Modat, David A. Drew, Long H. Nguyen, Lorenzo Polidori, Somesh Selvachandran, Christina Hu, Joan Capdevila, Alexander Hammers, Andrew T. Chan, Jonathan Wolf, Tins D. Spector, Claire J. Steves, Sebastien Ourselin

Summary: The study showed that the B.1.1.7 variant did not result in changes in COVID-19 symptoms or duration of illness, and there was no significant increase in reinfection rate compared to previous variants.

LANCET PUBLIC HEALTH (2021)

Article Medicine, Research & Experimental

Challenges and opportunities for conducting a vaccine trial during the COVID-19 pandemic in the United Kingdom

M. Estee Torok, Benjamin R. Underwood, Mark Toshner, Claire Waddington, Emad Sidhom, Katherine Sharrocks, Rachel Bousfield, Charlotte Summers, Caroline Saunders, Zoe McIntyre, Helen Morris, Jo Piper, Gloria Calderon, Sarah Dennis, Tracy Assari, Anita Marguerie de Rotrou, Ashley Shaw, John Bradley, John O'Brien, Robert C. Rintoul, Ian Smith, Ed Bullmore, Krishna Chatterjee

Summary: The text outlines the experience of rapidly setting up and conducting a novel COVID-19 vaccine trial in three National Health Service Trusts in Cambridgeshire, United Kingdom, overcoming various challenges through the establishment of a project team involving key members from all three organizations. By identifying best practices and procedures and harmonizing them within the wider trial team, they were able to set up the trial within 25 days and recruit and vaccinate participants within a further 23 days, lessons of which could be applied to future infectious disease pandemics or public health emergencies.

CLINICAL TRIALS (2021)

Article Medicine, General & Internal

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Amy Flaxman, Natalie G. Marchevsky, Daniel Jenkin, Jeremy Aboagye, Parvinder K. Aley, Brian Angus, Sandra Belij-Rammerstorfer, Sagida Bibi, Mustapha Bittaye, Federica Cappuccini, Paola Cicconi, Elizabeth A. Clutterbuck, Sophie Davies, Wanwisa Dejnirattisai, Christina Dold, Katie J. Ewer, Pedro M. Folegatti, Jamie Fowler, Adrian V. S. Hill, Simon Kerridge, Angela M. Minassian, Juthathip Mongkolsapaya, Yama F. Mujadidi, Emma Plested, Maheshi N. Ramasamy, Hannah Robinson, Helen Sanders, Emma Sheehan, Holly Smith, Matthew D. Snape, Rinn Song, Danielle Woods, Gavin Screaton, Sarah C. Gilbert, Merryn Voysey, Andrew J. Pollard, Teresa Lambe

Summary: The study shows that an extended interval before the second dose of the AstraZeneca vaccine leads to increased antibody titres, while a third dose significantly boosts antibody levels and enhances T-cell responses.

LANCET (2021)

Article Infectious Diseases

Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study

Katherine A. Twohig, Tommy Nyberg, Asad Zaidi, Simon Thelwall, Mary A. Sinnathamby, Shirin Aliabadi, Shaun R. Seaman, Ross J. Harris, Russell Hope, Jamie Lopez-Bernal, Eileen Gallagher, Andre Charlett, Daniela De Angelis, Anne M. Presanis, Gavin Dabrera

Summary: A study in England found that patients with COVID-19 infected with the delta variant were more likely to be admitted to hospital or attend emergency care compared to those infected with the alpha variant. This suggests that outbreaks of the delta variant in unvaccinated populations may pose a greater burden on healthcare services.

LANCET INFECTIOUS DISEASES (2022)

Article Cell Biology

Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7

Bo Meng, Steven A. Kemp, Guido Papa, Rawlings Datir, Isabella A. T. M. Ferreira, Sara Marelli, William T. Harvey, Spyros Lytras, Ahmed Mohamed, Giulia Gallo, Nazia Thakur, Dami A. Collier, Petra Mlcochova, Lidia M. Duncan, Alessandro M. Carabelli, Julia C. Kenyon, Andrew M. Lever, Anna De Marco, Christian Saliba, Katja Culap, Elisabetta Cameroni, Nicholas J. Matheson, Luca Piccoli, Davide Corti, Leo C. James, David L. Robertson, Dalan Bailey, Ravindra K. Gupta

Summary: The Delta H69N70 mutation in SARS-CoV-2 spike protein increases infectivity and partially rescues immune escape mutations that impair infectivity. Continued surveillance and research on deletions with functional effects are necessary.

CELL REPORTS (2021)

Article Biology

Superspreaders drive the largest outbreaks of hospital onset COVID-19 infections

Christopher J. R. Illingworth, William L. Hamilton, Ben Warne, Matthew Routledge, Ashley Popay, Chris Jackson, Tom Fieldman, Luke W. Meredith, Charlotte J. Houldcroft, Myra Hosmillo, Aminu S. Jahun, Laura G. Caller, Sarah L. Caddy, Anna Yakovleva, Grant Hall, Fahad A. Khokhar, Theresa Feltwell, Malte L. Pinckert, Iliana Georgana, Yasmin Chaudhry, Martin D. Curran, Surendra Parmar, Dominic Sparkes, Lucy Rivett, Nick K. Jones, Sushmita Sridhar, Sally Forrest, Tom Dymond, Kayleigh Grainger, Chris Workman, Mark Ferris, Effrossyni Gkrania-Klotsas, Nicholas M. Brown, Michael P. Weekes, Stephen Baker, Sharon J. Peacock, Ian G. Goodfellow, Theodore Gouliouris, Daniela de Angelis, M. Estee Torok

Summary: The study revealed an uneven pattern of transmission between individuals, with patients more likely to be infected by other patients. The data also showed a pattern of superspreading, where 21% of individuals caused 80% of transmission events.
Review Infectious Diseases

The role of viral genomics in understanding COVID-19 outbreaks in long-term care facilities

Dinesh Aggarwal, Richard Myers, William L. Hamilton, Tehmina Bharucha, Niamh M. Tumelty, Colin S. Brown, Emma J. Meader, Tom Connor, Darren L. Smith, Declan T. Bradley, Samuel Robson, Matthew Bashton, Laura Shallcross, Maria Zambon, Ian Goodfellow, Meera Chand, Justin O'Grady, M. Estee Torok, Sharon J. Peacock, Andrew J. Page

Summary: This study reviewed all genomic epidemiology studies on COVID-19 in long-term care facilities (LTCFs) and found that staff and residents usually had identical or very similar SARS-CoV-2 genomes. Outbreaks typically involved one main cluster, and the same lineages persisted despite infection control measures. It was also observed that the sequencing technique was reliable over time, and when combined with local epidemiology, genomics could help identify probable transmission sources. Multiple studies detected transmission between LTCFs, and the mortality rate among residents was high regardless of the lineage.

LANCET MICROBE (2022)

Article Infectious Diseases

Rapid Whole Genome Sequencing of Serotype K1 Hypervirulent Klebsiella pneumoniae from an Undocumented Chinese Migrant

C. K. Macleod, F. A. Khokhar, B. Warne, R. Wick, R. Butcher, B. Cassimon, P. Hayden, K. Holt, M. E. Torok

Summary: This case report details the fatal outcome of an undocumented Chinese migrant in her 60s with a new diagnosis of diabetes mellitus, caused by a hypervirulent strain of Klebsiella pneumoniae. Despite treatment with broad-spectrum antibiotics and admission to the ICU, the patient died within 48 hours of hospital admission. Increased awareness of hypervirulent K. pneumoniae and the use of novel sequencing technologies are highlighted as important factors for diagnosis and management of this infection.

CASE REPORTS IN INFECTIOUS DISEASES (2021)

暂无数据